<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01099514</url>
  </required_header>
  <id_info>
    <org_study_id>2009-02-026</org_study_id>
    <nct_id>NCT01099514</nct_id>
  </id_info>
  <brief_title>Study of Nilotinib in Metastatic Melanoma With KIT Aberrations</brief_title>
  <official_title>Phase II Study of Nilotinib in Metastatic Melanoma With KIT Aberrations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Major response was observed to imatinib mesylate in KIT-mutated metastatic rectal melanoma&#xD;
      (Hodi FS et al, J Clin Oncol 26:2046-2051, 2008). In the ASCO annual meeting in 2009ar, KIT&#xD;
      mutations were reported to be present in 23% of acral and 15.2% of mucosal melanomas&#xD;
      (Heinrich MC et al, J Clin Oncol 26:2008 abstr 9016). Nilotinib is a novel tyrosine kinase&#xD;
      inhibitor (TKI) targeting KIT, PDGFR, and Bcr-Abl and inhibiting the proliferating of both&#xD;
      imatinib-sensitive and imatinib-resistant cells in vitro. Phase I study of nilotinib alone&#xD;
      and in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal&#xD;
      tumors (GIST) demonstrated significant activity (72% stable disease for nilotinib alone and&#xD;
      56% for nilotinib/imatinib combination) (Blay JY et al, J Clin Oncol 26:2008, abstr 10553).&#xD;
&#xD;
      Thus, we propose to conduct a phase II study of nilotinib in metastatic melanoma with KIT&#xD;
      mutations.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>response rate</measure>
    <time_frame>1~2 year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Metastatic Melanoma With KIT Aberration</condition>
  <arm_group>
    <arm_group_label>Nilotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nilotinib 400 mg (2 capsules) PO BID q 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nilotinib</intervention_name>
    <description>D1~ Nilotinib 400 mg (2 capsules) PO BID q 28 days</description>
    <arm_group_label>Nilotinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically or cytologically proven melanoma with stage IV or unresectable stage&#xD;
             III disease&#xD;
&#xD;
          2. Documented KIT aberration&#xD;
&#xD;
          3. Adequate organ function as defined by the following criteria:&#xD;
&#xD;
               -  Serum aspartate transaminase (AST); serum glutamic oxaloacetic transaminase&#xD;
                  (SGOT)) and serum alanine transaminase (ALT); serum glutamic pyruvic transaminase&#xD;
                  (SGPT)) ≤ 2.5 x local laboratory upper limit of normal (ULN), or AST and ALT less&#xD;
                  than or equal to 5 x ULN if liver function abnormalities are due to underlying&#xD;
                  malignancy&#xD;
&#xD;
               -  Total serum bilirubin ≤ 1.5 x ULN&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1500/µL&#xD;
&#xD;
               -  Platelets ≥ 100,000/µL&#xD;
&#xD;
               -  Hemoglobin ≥ 9.0 g/dL (may be transfused or erythropoietin treated)&#xD;
&#xD;
               -  Serum calcium ≤ 12.0 mg/dL&#xD;
&#xD;
               -  Serum creatinine ≤ 1.5 x ULN&#xD;
&#xD;
          4. Patients with CNS metastasis must have stable neurologic function without evidence of&#xD;
             CNS progression within 8 weeks&#xD;
&#xD;
          5. May have previous adjuvant therapy with interferon, vaccines or therapy with IL-2,&#xD;
             chemotherapy&#xD;
&#xD;
          6. At least one measurable lesion by RECIST criteria&#xD;
&#xD;
          7. ECOG PS 0-2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Major surgery or radiation therapy within 4 weeks of starting the study treatment.&#xD;
&#xD;
          2. History of or known carcinomatous meningitis, or evidence of symptomatic&#xD;
             leptomeningeal disease on screening CT or MRI scan.&#xD;
&#xD;
          3. Ongoing cardiac dysrhythmias of NCI CTCAE grade ≥ 2.&#xD;
&#xD;
          4. QTc &gt; 470 msec on baseline EKG.&#xD;
&#xD;
          5. Pregnancy or breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Samsung Cancer Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>April 6, 2010</study_first_submitted>
  <study_first_submitted_qc>April 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2010</study_first_posted>
  <last_update_submitted>December 28, 2015</last_update_submitted>
  <last_update_submitted_qc>December 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Jeeyun Lee</investigator_full_name>
    <investigator_title>Samsung medical center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

